Neuropathies

Neuroscience Research Communications

Volumn 26, Issue 3, 2000, Pages 227-239

  Ter Laak, M P ^a   Lankhorst, A J ^a   Schrama, L H ^a   Gispen, W H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cisplatin induced neurotoxicity; Diabetes mellitus; Experimental allergic neuritis; Guillain Barre

Indexed keywords

CISPLATIN;

ALLERGIC NEUROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; DIABETIC NEUROPATHY; DRUG INDUCED DISEASE; GAIT; GUILLAIN BARRE SYNDROME; HUMAN; NERVE CONDUCTION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; STREPTOZOCIN DIABETES;

EID: 0033944242     PISSN: 08936609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6769(200005/06)26:3<227::AID-NRC10>3.0.CO;2-B     Document Type: Review

References (76)

1. Williams PL, Hall SM. Chronic Wallerian degeneration- an in vivo and ultrastructural study. J Anat 1971;109:487-503.
2. Ballin RH, Thomas PK. Changes at the nodes of ranvier during wallerian degeneration: an electron microscope study. Acta Neuropathol Berl 1969;14:237-249.
3. Duce IR, Keen P. A light and electron microscope study of changes occurring at the cut ends following section of the dorsal roots of rat spinal nerves. Cell Tissue Res 1976;170:491-505.
4. Thomas PK, Ochoa J. Clinical features and differential diagnosis. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, editors. Peripheral neuropathy. Philadelphia: WB Saunders; 1993. p 749-774.
5. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981;10:222-226.
6. Notermans NC, Wokke JHJ, Jennekens FGI. Clinical work-up of a patient with a polyneuropathy. In: de Jong JMBV, editor. Handbook of clinical neurology; 1991. p 30-70.
7. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824.
8. Veglio M, Sivieri R. Prevalence of neuropathy in IDDM patients in Piemonte, Italy. The Neuropathy Study Group of the Italian Society for the Study of Diabetes, Piemonte Affiliate. Diabetes Care 1993;16:456-461.
9. Young MJ, Boulton AJM, MacLeod AF, Williams DRR, Sonsken PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinical population. Diabetologia 1993;36:150-154.
10. The DCCT research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-986.
11. Ewing DJ, Clarke BF. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrinol Metab 1986;15:855-888.
12. Ross MA. Neuropathies associated with diabetes. Med Clin North Am 1993;77:111-124.
13. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diab Metab Rev 1995;11:193-225.
14. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia 1994;37:643-650.
15. de Jager AE, Sluiter HJ. Clinical signs in severe Guillain-Barre syndrome: analysis of 63 patients. J Neurol Sci 1991;104:143-150.
16. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27 Suppl:S21-24.
17. Ropper AH. The Guillain-Barre syndrome. N Engl J Med 1992;326:1130-1136.
18. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 1997;176 Suppl 2:S92-98.
19. Lampert PW. Mechanism of demyelination in experimental allergic neuritis. Electron microscopic studies. Lab Invest 1969;20:127-138.
20. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-458.
21. Brechenmacher C, Vital C, Deminiere C, et al. Guillain-Barre syndrome: an ultrastructural study of peripheral nerve in 65 patients. Clin Neuropathol 1987;6:19-24.
22. Rosen JL, Brown MJ, Hickey WF, Rostami A. Early myelin lesions in experimental allergic neuritis. Muscle Nerve 1990;13:629-636.
23. Kaldor J, Speed BR. Guillain-Barre syndrome and Campylobacterjejuni: a serological study. Br Med J Clin Res Ed 1984;288:1867-1870.
24. Kuroki S, Haruta T, Yoshioka M, Kobayashi Y, Nukina M, Nakanishi H. Guillain-Barre syndrome associated with Campylobacter infection. Pediatr Infect Dis J 1991;10:149-151.
25. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barre syndrome and controls: correlation and prognosis. Ann Neurol 1993;34:130-135.
26. Van Der Meché FGA. Guillain-Barré syndrome and variants. In: Latov N, Wokke JHJ, Kelly jr JJ, editors. Immunological and infectious diseases of the peripheral nerves. Cambridge University Press; 1998. p 99-110.
27. Moran AP, Rietschel ET, Kosunen TU, Zahringer U. Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose. J Bacteriol 1991;173:618-626.
28. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a. J Exp Med 1993;178:1771-1775.
29. Iqbal A, Oger JJ, Arnason BG. Cell-mediated immunity in idiopathic polyneuritis. Ann Neurol 1981; 9 Suppl:65-69.
30. Taylor WA, Hughes RA. T lymphocyte activation antigens in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1989;24:33-39.
31. Hartung HP, Toyka KV. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barre syndrome. Ann Neurol 1990;27 Suppl:S57-63.
32. Hughes RA, Kadlubowski M, Gray IA, Leibowitz S. Immune responses in experimental allergic neuritis. J Neurol Neurosurg Psychiatry 1981;44:565-569.
33. Rosenberg B, Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969;222:385-386.
34. Kedar A, Cohen ME, Freeman AI. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: a case report. Cancer Treat Rep 1978; 62:819-821.
35. Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989;16:195-211.
36. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988;61:2192-2195.
37. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984;34:934-938.
38. Ashraf M, Scotchel PL, Krall JM, Flink EB. cis-Platinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol 1983;16:309-318.
39. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 1989;25:62-64.
40. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54:1269-1275.
41. Cavaletti G, Tredici G, Pizzini G, Minoia A. Tissue platinum concentrations and cisplatin schedules. Lancet 1990;336:1003
42. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10:795-803.
43. Cece R, Petruccioli MG, Cavaletti G, Barajon I, Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations.Histol Histopathol 1995;10:837-845.
44. Barajon I, Bersani M, Quartu M, et al. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol 1996;138:93-104.
45. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol Berl 1992;84:364-371.
46. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998;101:2842-2850.
47. Zwelling LA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979;39:365-369.
48. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-790.
49. Mong S, Huang CH, Prestayko AW, Crooke ST. Interaction of cis-diamminedichloroplatinum (II) with PM-2 DNA. Cancer Res 1980;40:3313-3317.
50. Pascoe JM, Roberts JJ. Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand cross-linking and cytotoxic properties of platinum (II) compounds. Biochem Pharmacol 1974;23:1359-1365.
51. Pascoe JM, Roberts JJ. Interactions between mammalian cell DNA and inorganic platinum compounds. Biochem Pharmacol 1974;23:1345-1357.
52. Terheggen PM, van der Hoop RG, Floot BG, Gispen WH. Cellular distribution of cis-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: effect of the neuroprotecting peptide ORG.2766. Toxicol Appl Pharmacol 1989;99:334-343.
53. Blisard KS, Rogers SL, Alexander S, Harrington DA. Neurotoxic effects of platinum compounds in cultured dorsal root ganglion cells. J Exp Pathol 1992;6:65-74.
54. Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol Berl 1986;69:295-308.
55. Cece R, Petruccioli MG, Pizzini G, Cavaletti G, Tredici G. Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. J Submicrosc Cytol Pathol 1995;27:417-425.
56. Jakobsen J. Peripheral nerves in early experimental diabetes: expansion of the endoneurial space as a cause of increased water content. Diabetologia 1978;14:113-119.
57. Greene DA, Lattimer SA, Sima AA. Pathogenesis and prevention of diabetic neuropathy. Diabetes Metab Rev 1988;4:201-221.
58. Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984;107:935-950.
59. Kappelle AC, Biessels GJ, van Buren T, Erkelens DW, de Wildt DJ, Gispen WH. Effects of nimodipine on sciatic nerve blood flow and vasa nervorum responsiveness in the diabetic rat. Eur J Pharmacol 1993;250:43-49.
60. Biessels GJ, Stevens EJ, Mahmood SJ, Gispen WH, Tomlinson DR. Insulin partially reverses deficits in peripheral nerve blood flow and conduction in experimental diabetes (published erratum appears in J Neurol Sci 1996 Dec;144(1-2):234). J Neurol Sci 1996;140:12-20.
61. Amthor KF, Dahl Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994;37:579-584.
62. Constantinescu CS, Hilliard B, Fujioka T, Bhopale MK, Calida D, Rostami AM. Pathogenesis of neuroimmunologic diseases. Experimental models. Immunol Res 1998;17:217-227.
63. Brostoff S, Burnett P, Lampert P, Eylar EH. Isolation and characterization of a protein from sciatic nerve myelin responsible for experimental allergic neuritis. Nature New Biol 1972;235:210-212.
64. Linington C, Izumo S, Suzuki M, Uyemura K, Meyermann R, Wekerle H. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. J Immunol 1984;133:1946-1950.
65. Rostami A, Gregorian SK. Peptide 53-78 of myelin P2 protein is a T cell epitope for the induction of experimental autoimmune neuritis. Cell Immunol 1991;132:433-441.
66. Milner P, Lovelidge CA, Taylor WA, Hughes RA. P0 myelin protein produces experimental allergic neuritis in Lewis rats. J Neurol Sci 1987;79:275-285.
67. Lemke G, Axel R. Isolation and sequence of a cDNA encoding the major structural protein of peripheral myelin. Cell 1985;40:501-508.
68. Greenfield S, Brostoff S, Eylar EH, Morell P. Protein composition of myelin of the peripheral nervous system. J Neurochem 1973;20:1207-1216.
69. Brosnan JV, King RH, Thomas PK, Craggs RI. Disease patterns in experimental allergic neuritis (EAN) in the Lewis rat. Is EAN a good model for the Guillain-Barre syndrome? J Neurol Sci 1988;88:261-276.
70. Taylor WA, Hughes RA. Responsiveness to P2 of blood- and cauda equina-derived lymphocytes in experimental allergic neuritis in the Lewis rat: preliminary characterisation of a P2-specific cauda equina-derived T cell line. J Neuroimmunol 1988;19:279-289.
71. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 1979;63:1527-1531.
72. de Koning P, Neijt JP, Jennekens FG, Gispen WH. Org.2766 protects from cisplatin-induced neurotoxicity in rats. Exp Neurol 1987;97:746-750.
73. de Koning P, Brakkee JH, Gispen WH. Methods for producing a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function. Beneficial effects of melanocortins. J Neurol Sci 1986;74:237-246.
74. de Koning P, Gispen WH. Org. 2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 1987;8:415-422.
75. de Medinaceli L, Freed WJ, Wyatt RJ. An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks. Exp Neurol 1982;77:634-643.
76. Gerritsen van der Hoop R, Vecht Ch, Elderson A, Van den Burg MEL, Haanstra W, Ten Bokkel Huinink W, Heiman J, Vermarken J, Jennekens FGI, Gispen WH, Neijt JP. ORG 2766, an ACTH 4-9 analog, prevents cisplatin induced neuropathy in ovarian cancer patients. New Eng J Med 1991;322: 89-94.